Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Nicola Goekbuget
- Target Recruit Count
- 650
- Registration Number
- NCT00199082
- Locations
- π©πͺ
University Hospital, Medical Dept. II, Frankfurt, Germany
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 40
- Registration Number
- NCT00199095
- Locations
- π©πͺ
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 225
- Registration Number
- NCT00199056
- Locations
- π©πͺ
University Hospital, Medical Dept. II, Frankfurt, Germany
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193505
- Locations
- πΊπΈ
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165139
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 280
- Registration Number
- NCT00148395
- Locations
- π©πͺ
Klinikum Kassel GmbH, Kassel, Germany
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00147225
- Locations
- πΊπΈ
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1334
- Registration Number
- NCT00134030
- Locations
- πΊπΈ
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
πΊπΈGolisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00126191
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 263
- Registration Number
- NCT00104676
- Locations
- πΊπΈ
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
π«π·Centre Henri Becquerel, Rouen, France
πΈπ°National Cancer Institute - Bratislava, Bratislava, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.